SCHEMBL628490

SCHEMBL628490

[CH2]COCS

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2487 0.71
SCHEMBL6082244 0.69
SCHEMBL5248014 0.69
SCHEMBL5248811 0.65
SCHEMBL5597206 0.65
SCHEMBL51018 0.64
SCHEMBL13870432 0.64
SCHEMBL51690 0.64
SCHEMBL9817063 0.64
SCHEMBL3492930 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10927071-B2 Process for preparing electron deficient olefins Henkel IP & Holding GmbH (DE) 2021-02-23 US claimed
EP-3558934-A1 PROCESS FOR PREPARING ELECTRON DEFICIENT OLEFINS Henkel IP & Holding GmbH (DE) 2019-10-30 EP claimed
US-20190292141-A1 PROCESS FOR PREPARING ELECTRON DEFICIENT OLEFINS HENKEL AG & CO. KGAA (DE) 2019-09-26 US claimed
US-20180340008-A1 ANTIBIOTIC OLIGOPEPTIDE MIMETICS BIOXINESS PHARMACEUTICALS INC (US) 2018-11-29 US claimed
WO-2018114458-A1 PROCESS FOR PREPARING ELECTRON DEFICIENT OLEFINS Henkel IP & Holding GmbH (DE) 2018-06-28 WO claimed
US-7223757-B2 Tyrosine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-29 US claimed
US-7067658-B2 Pyridino and pyrimidino pyrazinones BRISTOL-MYERS SQUIBB COMPANY (US) 2006-06-27 US claimed
US-20060079518-A1 Novel tyrosine kinase inhibitors WITTMAN MARK D 2006-04-13 US claimed
US-20040082784-A1 Pyridino and pyrimidino pyrazinones BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-04-29 US claimed
WO-2004031189-A1 PYRIDINO AND PYRIMIDINO PYRAZINONES FOR TREATMENT OF ANXIETY AND DEPRESSION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2004-04-15 WO claimed
US-20040044203-A1 Novel tyrosine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-03-04 US claimed
US-6693123-B2 (4-(3-PYRIDYLAMINOMETHYLENE)-2-PHENYLBENZOYL)-N -METHYLMETHIONINE, METHYL ESTER FOR EXAMPLE; RESTENOSIS, HYPERPLASIA UNIVERSITY OF PITTSBURGH 2004-02-17 US claimed
US-20040006093-A1 Compounds which inhibit leukocyte adhesion mediated by VLA-4 BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) 2004-01-08 US claimed
US-6583139-B1 Treatment of inflammatory diseases; inflammatory brain diseases such as multiple sclerosis; N-(Toluene-4-sulfonyl)-L-prolyl-4-(alpha -methylbenzyloxy)-L-phenylalanine; Very Late Antigen 4 BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) 2003-06-24 US claimed
EP-0994896-A1 SULFONYLATED DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 Elan Pharmaceuticals, Inc. (US) 2000-04-26 EP claimed
WO-1999006437-A1 SULFONYLATED DIPEPTIDE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 ELAN PHARMACEUTICALS INC. (US) 1999-02-11 WO claimed
EP-3279373-B1 SILICONE-MODIFIED POLYURETHANE-BASED FIBER AND METHOD FOR MANUFACTURING SAME SHINETSU CHEMICAL CO (JP) 2024-03-06 EP disclosed
EP-3689979-B1 CATIONIC ELECTRODEPOSITION COATING COMPOSITION KANSAI PAINT CO LTD (JP) 2024-01-31 EP disclosed
WO-1995010519-A1 QUINOLIZINONE TYPE COMPOUNDS ABBOTT LABORATORIES (US) 1995-04-20 WO disclosed
WO-1994007518-A1 ANAPHYLATOXIN RECEPTOR LIGANDS CONTAINING LIPOPHILIC RESIDUES ABBOTT LABORATORIES (US) 1994-04-14 WO disclosed